Novel Opportunities for the Development of Drugs and Biologics in Cancer Supportive Care

Presented By: 
Stephen Sonis
Maria Mancini
Jonathan Zombeck
Gregory Lyng


Overview: While innovative therapeutic options have resulted in increasing successes in cancer treatment, the collateral damage associated with cancer regimen-related toxicities is profound. Almost three quarters of patients undergoing cancer therapy develop treatment-associated side effects of such severity as to negatively impact patients’ ability to tolerate treatment, increase their risk of co-morbidities, and adversely affect quality of life. Additionally, regimen-related toxicities add significantly to the cost of care. Debilitating toxicities such as mucositis, dermatitis, proctitis and fatigue are common consequences of many forms of chemo- or radiation therapy and their sequelae may persist long after active cancer treatment is finished.

Fortunately, there is now widespread interest for the development of interventions that effectively mitigate cancer treatment side effects without disrupting effective tumor kill. Robust predictive animal models that accurately translate to the specific human disease state are essential for the proper development of drugs and biologics. This webinar will review several sophisticated cancer supportive care preclinical models as well as novel approaches which will provide clinical relevance and in return enable a company to confidently characterize the biological outcomes anticipated in humans.

Request Slide Deck.